A consirtsium of investors led a $121m Series C funding round in Cellarity, a pharmaceutical company, with participation from Flagship Pioneering, Kyowa Kirin and Hanwha Impact Partners. “Cellarity is truly rewriting the rules of drug creation. Disease isn’t driven by one mechanism or protein, so Cellarity has developed the ability to solve disease through the lens of the entire cell. Since the cell is a fuller representation of disease, the platform is uniquely designed to drive higher translatability and clinical success, creating important new medicines for internal pipeline development as well as with partners," Stephen Berenson, Cellarity Board of Directors Chairperson and Flagship Pioneering Managing Partner.